Why is there a lack of comprehensive studies providing granular insights into the costs of therapeutic programs in big pharma and biotechnology companies? | Roamingdesk.com
The lack of comprehensive studies providing granular insights into the costs of therapeutic programs in big pharma and biotechnology companies can be attributed to several factors: Confidentiality and Intellectual Property Concerns: Pharmaceutical and biotechnology companies often consider their research and development activities to be proprietary and competitive advantages. Disclosing detailed cost breakdowns could potentially